Show simple item record

dc.contributor.authorKhan, O A
dc.contributor.authorGore, M
dc.contributor.authorLorigan, Paul C
dc.contributor.authorStone, J
dc.contributor.authorGreystoke, Alastair
dc.contributor.authorBurke, W
dc.contributor.authorCarmichael, J
dc.contributor.authorWatson, Amanda J
dc.contributor.authorMcGown, Gail
dc.contributor.authorThorncroft, Mary R
dc.contributor.authorMargison, Geoffrey P
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorLarkin, J
dc.contributor.authorWellman, S
dc.contributor.authorMiddleton, M R
dc.date.accessioned2012-01-04T22:58:28Z
dc.date.available2012-01-04T22:58:28Z
dc.date.issued2011-03-01
dc.identifier.citationA phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. 2011, 104 (5):750-5 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid21326243
dc.identifier.doi10.1038/bjc.2011.8
dc.identifier.urihttp://hdl.handle.net/10541/200184
dc.description.abstractPoly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to tumour cells and augments the anti-tumour effects of DNA-damaging agents. This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clinical pharmacokinetics and efficacy of combination treatment.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshDacarbazine
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMaximum Tolerated Dose
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshNeutropenia
dc.subject.meshPhthalazines
dc.subject.meshPiperazines
dc.subject.meshPoly(ADP-ribose) Polymerases
dc.subject.meshThrombocytopenia
dc.titleA phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.en
dc.typeArticleen
dc.contributor.departmentUniversity of Oxford Department of Oncology, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK.en
dc.identifier.journalBritish Journal of Canceren
dc.identifier.pmcidPMC3048218
html.description.abstractPoly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to tumour cells and augments the anti-tumour effects of DNA-damaging agents. This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clinical pharmacokinetics and efficacy of combination treatment.


This item appears in the following Collection(s)

Show simple item record